A new cancer treatment will be sold for nearly half a million dollars, sparking criticism from some patient advocates.
On Wednesday, the Food and Drug Administration approved the first gene therapy in the U.S. called Kymriah, which customize a patient’s own immune cells to fight a type of leukemia through a therapy called CAR-T.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.